Iambic Therapeutics shares are trading lower amid post-IPO volatility IPO priced at $16.00 per share raising $150.0 million gross proceeds Stock began trading on Nasdaq on October 15, 2026 ...

Clinical-stage cancer drug and tech firm Iambic Therapeutics raised $150 million in its U.S. IPO, then surged about 18% on day one. Shares finished Thursday at $18.91 versus a $16 offer price, ...

Iambic Therapeutics just found out what public investors think of an AI-powered cancer drug developer. The answer, at least on day one, was enthusiastic. The San Diego biotech’s shares rose 16% to $18 ...

Iambic Therapeutics完成美国IPO，融资1.5亿美元，以每股16美元发行约938万股，原定区间15至17美元，IPO后市值7.58亿美元，募资用于三款早期抗癌候选药物。 观点网讯：10月15日消息，临床阶段抗癌药物 ...

Iambic Therapeutics (IAM) announced the pricing of its initial public offering of 9.38M shares of common stock at $16.00 per share. The offering is expected to generate gross proceeds of $150M. All ...

Iambic Therapeutics (IAM) priced its initial public offering of about 9.38 million shares at $16.00 each, it said late Wednesday, targeting about $150 million in gross proceeds. The company, which is ...

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today ...

The company’s stock is set to start trading on the Nasdaq on Thursday morning under the ticker symbol “IAM.” (VIEW press / Contributor) Iambic Therapeutics’ IPO came in dead on target, bringing in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, raised $150 million by offering 9.4 million shares at $16, within the $15 to $17 range.